Comparing Beigene (ONC) & The Competition

Beigene (NASDAQ:ONC) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Beigene to similar businesses based on the strength of its earnings, analyst recommendations, institutional ownership, valuation, risk, dividends and profitability.

Risk and Volatility

Beigene has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Beigene’s competitors have a beta of 3.86, indicating that their average stock price is 286% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Beigene and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beigene	0	0	3	0	3.00
Beigene Competitors	8400	22240	50400	1348	2.54

Beigene presently has a consensus price target of $310.00, suggesting a potential upside of 29.97%. As a group, “Pharmaceutical preparations” companies have a potential upside of 258.80%. Given Beigene’s competitors higher possible upside, analysts plainly believe Beigene has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Beigene and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Beigene	$3.81 billion	-$881.71 million	-38.85
Beigene Competitors	$9.89 billion	$136.37 million	-5.52

Beigene’s competitors have higher revenue and earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Beigene and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beigene	-25.94%	-25.12%	-14.95%
Beigene Competitors	-3,399.87%	-235.11%	-32.77%

Institutional and Insider Ownership

48.5% of Beigene shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 7.4% of Beigene shares are owned by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Beigene competitors beat Beigene on 7 of the 13 factors compared.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.